Annex Advisory Services LLC Grows Stock Holdings in Amgen Inc. $AMGN

Annex Advisory Services LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 12,757 shares of the medical research company’s stock after purchasing an additional 1,905 shares during the period. Annex Advisory Services LLC’s holdings in Amgen were worth $4,176,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in AMGN. Board of the Pension Protection Fund purchased a new position in Amgen in the 4th quarter worth approximately $26,000. Olistico Wealth LLC purchased a new position in Amgen in the 4th quarter worth approximately $33,000. Cloud Capital Management LLC purchased a new position in Amgen in the 3rd quarter worth approximately $34,000. Saranac Partners Ltd purchased a new position in Amgen in the 3rd quarter worth approximately $37,000. Finally, Holos Integrated Wealth LLC purchased a new position in Amgen in the 4th quarter worth approximately $37,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN opened at $350.95 on Wednesday. The firm has a market cap of $189.40 billion, a PE ratio of 24.66, a P/E/G ratio of 3.29 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a fifty day simple moving average of $364.22 and a two-hundred day simple moving average of $336.58. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent analyst reports. UBS Group boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Royal Bank Of Canada boosted their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Truist Financial boosted their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Finally, Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $356.24.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.